Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of “Buy” by Analysts

Annovis Bio, Inc. (NYSE:ANVS) has been given a consensus recommendation of “Buy” by the six brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $37.00.

Several brokerages have recently weighed in on ANVS. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Annovis Bio in a research note on Monday, November 11th. D. Boral Capital reissued a “hold” rating on shares of Annovis Bio in a research note on Monday, February 10th.

Annovis Bio Stock Down 0.9 %

Shares of NYSE:ANVS opened at $1.68 on Friday. The firm has a fifty day simple moving average of $3.74 and a two-hundred day simple moving average of $6.32. Annovis Bio has a 52 week low of $1.57 and a 52 week high of $20.00. The stock has a market capitalization of $23.85 million, a P/E ratio of -0.38 and a beta of 1.65.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ANVS. JPMorgan Chase & Co. acquired a new position in shares of Annovis Bio in the third quarter valued at about $31,000. Two Sigma Investments LP acquired a new position in Annovis Bio in the 4th quarter worth approximately $55,000. XTX Topco Ltd purchased a new position in Annovis Bio during the 4th quarter worth approximately $59,000. Atria Wealth Solutions Inc. acquired a new stake in Annovis Bio during the 4th quarter valued at approximately $65,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Annovis Bio in the 3rd quarter valued at $76,000. Hedge funds and other institutional investors own 15.83% of the company’s stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.